Last $159.60 USD
Change Today +0.41 / 0.26%
Volume 2.5M
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$160.00
Previous Close
$159.19
Day High
$161.48
Day Low
$158.86
52 Week High
12/8/14 - $173.14
52 Week Low
04/28/14 - $108.20
Market Cap
121.1B
Average Volume 10 Days
3.0M
EPS TTM
$7.56
Shares Outstanding
758.9M
EX-Date
05/12/15
P/E TM
21.1x
Dividend
$3.16
Dividend Yield
1.64%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Announces Second Quarter 2015 Dividend, Payable on June 5, 2015

Amgen announced that its Board of Directors declared a $0.79 per share dividend for the second quarter of 2015. The dividend will be paid on June 5, 2015, to all stockholders of record as of the close of business on May 14, 2015.

Amgen Inc. Appoints Annette L. Such as Chief Accounting Officer, Effective March 9, 2015

On March 4, 2015, Amgen Inc. announced the appointment of Annette L. Such, age 46, to serve as the Company's Chief Accounting Officer (CAO), effective as of March 9, 2015. Ms. Such will be the Company's principal accounting officer; she will not be an executive officer of the Company. The Board of Directors of the Company appointed Ms. Such to this position on March 4, 2015. Ms. Such has served as the Company's Executive Director, Technical Accounting and External Reporting since she was hired in June 2012. From March 2012 through May 2012, Ms. Such was Vice President of Accounting at Dell Inc., a computer technology company, where she also served as Executive Director of Accounting from May 2005 until March 2012.

Celimmune and Amgen Sign Licensing Agreement for IL-15 mAb in Coeliac Disease

Celimmune has announced that it has licensed AMG 714, an investigational interleukin 15 (IL-15) monoclonal antibody (mAb), from Amgen. Under the terms of the agreement, Celimmune has obtained the rights to develop, manufacture, and commercialise the candidate globally, expect for Japan. Amgen will have the option to reacquire AMG 714 following the completion of certain clinical trials. Celimmune has announced plans to launch Phase II studies for AMG 714 as potential treatment for coeliac disease that is non-responsive to diet and refractory coeliac disease (RCD).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $159.60 USD +0.41

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.44 USD +0.43
AbbVie Inc $56.86 USD -3.41
Bristol-Myers Squibb Co $66.05 USD +0.38
Eli Lilly & Co $70.59 USD -0.06
Novo Nordisk A/S kr321.00 DKK +3.00
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 23.8x
Price/Sales 6.0x
Price/Book 4.7x
Price/Cash Flow 23.4x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.